Genetic Susceptibility to Distinct Bladder Cancer Subphenotypes

European Urology

Volumn 57, Issue 2, 2010, Pages 283-292

  Guey, Lin T ^a,e   García Closas, Montserrat ^b   Murta Nascimento, Cristiane ^e   Lloreta, Josep ^c,d   Palencia, Laia ^e   Kogevinas, Manolis ^e,f,g,h   Rothman, Nathaniel ^b   Vellalta, Gemma ^e   Calle, M Luz ⁱ   Marenne, Gaëlle ^a   Tardón, Adonina ^j   Carrato, Alfredo ^k   García Closas, Reina ^l   Serra, Consol ^m   Silverman, Debra T ^b   Chanock, Stephen ^b   Real, Francisco X ^a,d,e   Malats, Núria ^a,e  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^f CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^g UNIVERSITY OF CRETE   (Greece)

^h CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

ⁱ UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

^j UNIVERSITY OF OVIEDO   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^l HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^m Department of Pediatrics   (Spain)

more..

Author keywords

Genetic polymorphism; Heterogeneity; Pathologic characteristics; Tumour subphenotypes; Urinary bladder cancer

Indexed keywords

GLUTATHIONE TRANSFERASE M1; PROTEIN NAT2; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACETYLATION; ADULT; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER INVASION; CASE CONTROL STUDY; CLINICAL FEATURE; CONFOUNDING VARIABLE; CONTROLLED STUDY; EXPLORATORY RESEARCH; FEMALE; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; UROGENITAL TRACT CANCER; WORLD HEALTH ORGANIZATION;

AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; URINARY BLADDER NEOPLASMS;

EID: 72149083027     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.08.001     Document Type: Article

References (31)

1. Ferlay JBF, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, Version 2.0. Lyon, France: IARC Press; 2004.
2. Lotan Y., Svatek R.S., and Malats N. Screening for bladder cancer: a perspective. World J Urol 26 (2008) 13-18
3. Mostofi F.K., Davis C.J., and Sesterhenn I. Histological typing of urinary bladder tumours. 2nd ed. (1999), Springer, Berlin, Germany
4. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
5. Pasin E., Josephson D.Y., Mitra A.P., Cote R.J., and Stein J.P. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10 (2008) 31-43
6. Wu X.R. Urothelial tumourigenesis: a tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
7. Lopez-Knowles E., Hernandez S., Malats N., et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumours. Cancer Res 66 (2006) 7401-7404
8. Samanic C., Kogevinas M., Dosemeci M., et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 15 (2006) 1348-1354
9. Silverman D.T., Devesa S.S., Moore L.E., and Rothman N. Bladder cancer. In: Schottenfeld D., and Fraumeni Jr. J.F. (Eds). Cancer epidemiology and prevention. 3rd ed. (2006), Oxford University Press, New York, NY 1101-1127
10. Sturgeon S.R., Hartge P., Silverman D.T., et al. Associations between bladder cancer risk factors and tumour stage and grade at diagnosis. Epidemiology 5 (1994) 218-225
11. Garcia-Closas M., Malats N., Silverman D., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366 (2005) 649-659
12. Garcia-Closas M., Malats N., Real F.X., et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 3 (2007) e29
13. Malats N. Genetic epidemiology of bladder cancer: scaling up in the identification of low penetrance genetic markers of bladder cancer risk and progression. WHO Bladder Cancer report. Scand J Urol Nephrol Suppl 218 (2008) 131-140
14. Garcia-Closas M., Hall P., Nevanlinna H., et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4 (2008) e1000054
15. Thomas G., Jacobs K.B., Yeager M., et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40 (2008) 310-315
16. Hernandez S., Lopez-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24 (2006) 3664-3671
17. Greene FL. American Joint Committee on Cancer; American Cancer Society. AJCC cancer staging manual. 6th ed. (2002), Springer, New York, NY
18. Benjamini Y., Drai D., Elmer G., Kafkafi N., and Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125 (2001) 279-284
19. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 (2006) 361-373
20. Garred P., Larsen F., Seyfarth J., Fujita R., and Madsen H.O. Mannose-binding lectin and its genetic variants. Genes Immun 7 (2006) 85-94
21. Baccarelli A., Hou L., Chen J., et al. Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int J Cancer 119 (2006) 1970-1975
22. Bernig T., Boersma B.J., Howe T.M., et al. The mannose-binding lectin (MBL2) haplotype and breast cancer: an association study in African-American and Caucasian women. Carcinogenesis 28 (2007) 828-836
23. Pine S.R., Mechanic L.E., Ambs S., et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. J Natl Cancer Inst 99 (2007) 1401-1409
24. Dossou-Yovo O.P., Lapoumeroulie C., Hauchecorne M., et al. Variants of the mannose-binding lectin gene in the Benin population: heterozygosity for the p.G57E allele may confer a selective advantage. Hum Biol 79 (2007) 687-697
25. Hraber P., Kuiken C., and Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 46 (2007) 1713-1721
26. Landi M.T., Baccarelli A., Tarone R.E., et al. DNA repair, dysplastic nevi, and sunlight sensitivity in the development of cutaneous malignant melanoma. J Natl Cancer Inst 94 (2002) 94-101
27. Schneider H.J., Saller B., Klotsche J., et al. Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 154 (2006) 699-706
28. Weiss N.S. Subgroup-specific associations in the face of overall null results: should we rush in or fear to tread?. Cancer Epidemiol Biomarkers Prev 17 (2008) 1297-1299
29. Kwan T., Benovoy D., Dias C., et al. Heritability of alternative splicing in the human genome. Genome Res 17 (2007) 1210-1218
30. Hull J., Campino S., Rowlands K., et al. Identification of common genetic variation that modulates alternative splicing. PLoS Genet 3 (2007) e99
31. Kiemeney L.A., Thorlacius S., Sulem P., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 40 (2008) 1307-1312